PolyPid (PYPD) Competitors

PolyPid (NASDAQ:PYPD) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Does the MarketBeat Community believe in PYPD or INFU?

PolyPid received 22 more outperform votes than InfuSystem when rated by MarketBeat users. However, 100.00% of users gave InfuSystem an outperform vote while only 79.49% of users gave PolyPid an outperform vote.

Company	Underperform	Outperform
PolyPid	Outperform Votes 31 79.49%	Underperform Votes 8 20.51%
InfuSystem	Outperform Votes 9 100.00%	Underperform Votes No Votes

Does the media favor PYPD or INFU?

In the previous week, PolyPid and PolyPid both had 3 articles in the media. InfuSystem's average media sentiment score of 0.50 beat PolyPid's score of -0.36 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
InfuSystem	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in PYPD or INFU?

26.5% of PolyPid shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 10.2% of InfuSystem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has stronger valuation & earnings, PYPD or INFU?

InfuSystem has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$29.02M	-$4.97	-0.56
InfuSystem	$134.86M	0.96	$870K	$0.10	61.50

Which has more volatility and risk, PYPD or INFU?

PolyPid has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500.

Do analysts recommend PYPD or INFU?

PolyPid currently has a consensus target price of $11.33, indicating a potential upside of 304.76%. InfuSystem has a consensus target price of $13.00, indicating a potential upside of 111.38%. Given PolyPid's higher probable upside, analysts plainly believe PolyPid is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
InfuSystem	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	4.00

Is PYPD or INFU more profitable?

InfuSystem has a net margin of 1.12% compared to PolyPid's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-624.10%	-129.28%
InfuSystem	1.12%	2.78%	1.41%

Summary

InfuSystem beats PolyPid on 13 of the 17 factors compared between the two stocks.